19
Sep
2019
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
17
Sep
2019
A Nonprofit That Carried a TB Drug Through the FDA: Bruce Carter on The Long Run
Today’s guest on The Long Run is Bruce Carter. Bruce is the chairman of the board at the New York-based TB Alliance. He’s a senior statesman of the industry, known for his run as CEO of Seattle-based ZymoGenetics, and for serving on a variety of boards. He’s the chairman of the board at Watertown, Mass.-based Enanta Pharmaceuticals, the developer of...Read More
Share:
12
Sep
2019
10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
5
Sep
2019
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
4
Sep
2019
Making a Difference for Sickle Cell Disease: Ted Love on The Long Run
Today’s guest on The Long Run is Ted Love. Ted is the CEO of Global Blood Therapeutics, known as GBT for short. The company, based in South San Francisco, is on the cusp of bringing forward the first innovative, disease-modifying medicine for sickle cell disease. GBT has run a pivotal clinical trial in 274 patients, gotten the results published in...Read More
Share:
29
Aug
2019
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
Aug
2019
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Aug
2019
An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook
The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause...Read More
Share:
20
Aug
2019
Getting in on the Ground Floor of the Biotech Boom: Joel Marcus on The Long Run
Today’s guest on The Long Run is Joel Marcus. Joel is the executive chairman and founder of Alexandria Real Estate Equities. If you have spent five minutes in the biotech industry, you’ve been in one of his buildings. Alexandria is one of just a couple of the big real-estate investment trusts (REITs) that cater to the life sciences industry. ARE...Read More
Share:
15
Aug
2019
Roche/Genentech’s Clever NTRK Strategy, Regeneron’s Ebola Win & PCR Pioneer Passes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
Aug
2019
Novartis’ No-No, Bayer Buys BlueRock, and Job Switches Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
Aug
2019
From Pharma VC to Cell Therapy Startup: Janelle Anderson on The Long Run
Today’s guest on The Long Run is Janelle Anderson. Janelle is the chief strategy officer of Century Therapeutics. This is a company using induced pluripotent stem cells to make off-the-shelf cell therapies for cancer. This is the new dream of cell therapy, as scientists imagine ways to lower the cost and expand access for patients following the first wave of...Read More
Share:
11
Jul
2019
Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run
Today’s guest on The Long Run is Cindy Perettie. Cindy is the CEO of Cambridge, Mass.-based Foundation Medicine. This company does genomic analysis on tumors. If you know more of this molecular nitty-gritty information – things like the underlying gene mutations that send cancer cells into out-of-control growth sprees – then you ought to occasionally come up with more effective...Read More
Share:
11
Jul
2019
BioNTech Snags $320m, Roche/Spark Delay, & Summer Job Switches
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
2
Jul
2019
Cancer Survivor and Cancer Drug Developer: Laura Shawver on The Long Run
Today’s guest on The Long Run is Laura Shawver. Laura is the CEO of San Diego-based Synthorx. This company, based on research from The Scripps Research Institute, is using a couple of newly invented base pairs of DNA to make site-specific modifications on fully expressed proteins. This capability, Synthorx believes, could be put to practical use to craft ideal drug-like...Read More
Share:
27
Jun
2019
AbbVie & Allergan (Groan), Adaptive Headlines IPO Rush, & FDA Cops on the Beat
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
20
Jun
2019
Pfizer’s Wager on Small Molecules, Summer IPO Flurries, Gilead’s Protein Degrader Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
Jun
2019
Who Will Be the Next Celgene of Dealmaking?
Stars aligned beautifully, not long ago, for dealmaking at Celgene. The company, early this decade, was raking in the dough from the multiple myeloma drug Revlimid. Cash had to be spent somewhere. Celgene didn’t have much of its own R&D. Shareholders weren’t clamoring for their cut, via quarterly cash dividends. The stock soared, without any jet fueled-share buybacks. Letting cash...Read More
Share:
13
Jun
2019
Predicting Who Will Benefit from Cancer Drugs: Liz O’Day on The Long Run
Today’s guest on The Long Run is Liz O’Day. Liz is the founder and CEO of Cambridge, Mass.-based Olaris Therapeutics. This is a scrappy little startup that’s studying metabolites that could provide clues for predicting which patients are most likely to respond to certain cancer drugs. Figuring out which patients are likely to respond is one of those perennial challenges...Read More
Share:
30
May
2019
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: